CN104262344A - 艾德拉尼的制备方法 - Google Patents
艾德拉尼的制备方法 Download PDFInfo
- Publication number
- CN104262344A CN104262344A CN201410416005.2A CN201410416005A CN104262344A CN 104262344 A CN104262344 A CN 104262344A CN 201410416005 A CN201410416005 A CN 201410416005A CN 104262344 A CN104262344 A CN 104262344A
- Authority
- CN
- China
- Prior art keywords
- preparation
- purine
- amino
- delany
- dana
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SALXRNIYKLYOMW-UHFFFAOYSA-N CCC(C(N1c2ccccc2)=Nc(cccc2F)c2C1=O)NC1=C(C)C(NC=C=C)=NC=C=C1 Chemical compound CCC(C(N1c2ccccc2)=Nc(cccc2F)c2C1=O)NC1=C(C)C(NC=C=C)=NC=C=C1 SALXRNIYKLYOMW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410416005.2A CN104262344B (zh) | 2014-08-22 | 2014-08-22 | 艾德拉尼的制备方法 |
KR1020177007729A KR101934096B1 (ko) | 2014-08-22 | 2015-07-31 | 이델라리십의 제조방법 |
PCT/CN2015/085706 WO2016026380A1 (zh) | 2014-08-22 | 2015-07-31 | 艾德拉尼的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410416005.2A CN104262344B (zh) | 2014-08-22 | 2014-08-22 | 艾德拉尼的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104262344A true CN104262344A (zh) | 2015-01-07 |
CN104262344B CN104262344B (zh) | 2015-11-04 |
Family
ID=52153956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410416005.2A Active CN104262344B (zh) | 2014-08-22 | 2014-08-22 | 艾德拉尼的制备方法 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101934096B1 (zh) |
CN (1) | CN104262344B (zh) |
WO (1) | WO2016026380A1 (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104892612A (zh) * | 2015-04-15 | 2015-09-09 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
WO2016026380A1 (zh) * | 2014-08-22 | 2016-02-25 | 苏州明锐医药科技有限公司 | 艾德拉尼的制备方法 |
CN105943510A (zh) * | 2016-06-13 | 2016-09-21 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司制剂及其应用 |
CN106074430A (zh) * | 2016-06-13 | 2016-11-09 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司泡腾片及其制备方法 |
CN106146500A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 5-氟-3-苯基-2-[(1s)-1-(9h-嘌呤-6-基氨基)丙基]-4(3h)-喹唑啉酮晶型及其制备方法 |
CN106146501A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 一种无定型激酶抑制剂的制备方法 |
CN106146503A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | 一种Idelalisib的制备方法 |
CN106146352A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | Idelalisib中间体及其制备方法 |
WO2016188506A1 (en) * | 2015-05-22 | 2016-12-01 | Zentiva, K.S. | Solid forms of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof |
CN106632337A (zh) * | 2016-10-18 | 2017-05-10 | 湖北生物医药产业技术研究院有限公司 | 艾代拉里斯的晶型、药物组合物、制备方法和用途 |
WO2017093773A1 (en) * | 2015-11-30 | 2017-06-08 | Egis Gyógyszergyár Zrt. | New polymorphic and solvate form of idelalisib |
WO2017134607A1 (en) | 2016-02-03 | 2017-08-10 | Lupin Limited | A process for the preparation of phosphatidylinositol 3-kinase inhibitor |
WO2017191608A1 (en) * | 2016-05-05 | 2017-11-09 | Laurus Labs Limited | Novel process for preparation of idelalisib |
WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
CN108409740A (zh) * | 2018-03-14 | 2018-08-17 | 盐城师范学院 | 一种新的艾代拉里斯制备方法 |
CN111471001A (zh) * | 2020-05-20 | 2020-07-31 | 苏州明锐医药科技有限公司 | 4-[(1r)-1-氨基-2-羟基乙基]-3-氟-苯腈的制备方法 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015095605A1 (en) | 2013-12-20 | 2015-06-25 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one |
NZ720867A (en) | 2013-12-20 | 2018-01-26 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
WO2019178596A1 (en) | 2018-03-16 | 2019-09-19 | Johnson Matthey Public Limited Company | Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031569A (zh) * | 2004-05-13 | 2007-09-05 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
WO2013116562A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104262344B (zh) * | 2014-08-22 | 2015-11-04 | 苏州明锐医药科技有限公司 | 艾德拉尼的制备方法 |
-
2014
- 2014-08-22 CN CN201410416005.2A patent/CN104262344B/zh active Active
-
2015
- 2015-07-31 WO PCT/CN2015/085706 patent/WO2016026380A1/zh active Application Filing
- 2015-07-31 KR KR1020177007729A patent/KR101934096B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101031569A (zh) * | 2004-05-13 | 2007-09-05 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
WO2013116562A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Calistoga Llc | Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile |
Non-Patent Citations (1)
Title |
---|
GUILLERMO A. MORALES ET AL.,: "Synthesis and Cancer Stem Cell-Based Activity of Substituted 5‑Morpholino‑7H‑thieno[3,2‑b]pyran-7-ones Designed as Next Generation PI3K Inhibitors", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 56, no. 5, 14 February 2013 (2013-02-14), pages 1922 - 1939 * |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016026380A1 (zh) * | 2014-08-22 | 2016-02-25 | 苏州明锐医药科技有限公司 | 艾德拉尼的制备方法 |
CN106146500A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 5-氟-3-苯基-2-[(1s)-1-(9h-嘌呤-6-基氨基)丙基]-4(3h)-喹唑啉酮晶型及其制备方法 |
CN106146501A (zh) * | 2015-03-26 | 2016-11-23 | 江苏豪森药业集团有限公司 | 一种无定型激酶抑制剂的制备方法 |
WO2016165618A1 (zh) * | 2015-04-15 | 2016-10-20 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
US10370376B2 (en) | 2015-04-15 | 2019-08-06 | Alnova Pharmaceuticals, Ltd. | Amorphous substance of Idelalisib and preparation method therefor |
CN104892612A (zh) * | 2015-04-15 | 2015-09-09 | 上海方楠生物科技有限公司 | 一种艾德力布的无定型物及其制备方法 |
CN106146503A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | 一种Idelalisib的制备方法 |
CN106146352A (zh) * | 2015-04-16 | 2016-11-23 | 上海医药工业研究院 | Idelalisib中间体及其制备方法 |
WO2016188506A1 (en) * | 2015-05-22 | 2016-12-01 | Zentiva, K.S. | Solid forms of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof |
WO2017093773A1 (en) * | 2015-11-30 | 2017-06-08 | Egis Gyógyszergyár Zrt. | New polymorphic and solvate form of idelalisib |
WO2017134607A1 (en) | 2016-02-03 | 2017-08-10 | Lupin Limited | A process for the preparation of phosphatidylinositol 3-kinase inhibitor |
WO2017191608A1 (en) * | 2016-05-05 | 2017-11-09 | Laurus Labs Limited | Novel process for preparation of idelalisib |
CN106074430A (zh) * | 2016-06-13 | 2016-11-09 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司泡腾片及其制备方法 |
CN105943510A (zh) * | 2016-06-13 | 2016-09-21 | 佛山市腾瑞医药科技有限公司 | 一种艾代拉利司制剂及其应用 |
WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
CN106632337A (zh) * | 2016-10-18 | 2017-05-10 | 湖北生物医药产业技术研究院有限公司 | 艾代拉里斯的晶型、药物组合物、制备方法和用途 |
CN106632337B (zh) * | 2016-10-18 | 2018-11-20 | 湖北生物医药产业技术研究院有限公司 | 艾代拉里斯的晶型、药物组合物、制备方法和用途 |
CN108409740A (zh) * | 2018-03-14 | 2018-08-17 | 盐城师范学院 | 一种新的艾代拉里斯制备方法 |
CN111471001A (zh) * | 2020-05-20 | 2020-07-31 | 苏州明锐医药科技有限公司 | 4-[(1r)-1-氨基-2-羟基乙基]-3-氟-苯腈的制备方法 |
CN111471001B (zh) * | 2020-05-20 | 2023-05-26 | 上海鲲博玖瑞医药科技发展有限公司 | 4-[(1r)-1-氨基-2-羟基乙基]-3-氟-苯腈的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
KR101934096B1 (ko) | 2019-01-02 |
WO2016026380A1 (zh) | 2016-02-25 |
KR20170075713A (ko) | 2017-07-03 |
CN104262344B (zh) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104262344B (zh) | 艾德拉尼的制备方法 | |
CN108047261B (zh) | 一种克立硼罗的制备方法 | |
CN104130261B (zh) | 艾德利布的合成方法 | |
CN102584795B (zh) | 一种克里唑替尼的制备方法 | |
CN103508899A (zh) | 一种制备替格瑞洛关键中间体及其消旋体的方法和实施该方法的专用中间体 | |
EP2985286B1 (en) | Midbody of ticagrelor and preparation method therefor, and preparation method for ticagrelor | |
CN106068271B (zh) | 2′-取代-2,2′-脱水尿苷或2′-取代-2,2′-脱水胞苷化合物及其制备方法和用途 | |
CN105330643A (zh) | 卡比替尼的制备方法 | |
CN107216313A (zh) | 一种抗肿瘤药物azd9291的制备方法 | |
CN106749259A (zh) | 一种环戊基嘧啶并吡咯类化合物的合成方法 | |
CN108017593B (zh) | 一种简便高效的1-氧-4,5-二氮杂环庚烷合成方法 | |
CN102584732B (zh) | 一种制备普乐沙福的方法 | |
CN103772278A (zh) | 一种重要四氢异喹啉衍生物中间体及其合成方法 | |
CN104844549A (zh) | 一种7-溴吡喃衍生物的制备方法 | |
CN103980120A (zh) | 一种混旋丹参素异丙酯的合成方法 | |
KR20180096628A (ko) | 소니데깁의 제조 방법 | |
CN103694182B (zh) | 一种喹喔啉类化合物的制备方法 | |
CN103275056B (zh) | 一种替卡格雷中间体的制备方法 | |
CN108623602A (zh) | 一种制备和纯化依鲁替尼的方法 | |
CN102633802B (zh) | 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法 | |
CN104710417A (zh) | 氮杂吲哚类衍生物及其合成方法 | |
CN104059075B (zh) | 8,9-单,双取代的咪唑[1,2-c]-喹唑啉-3(2H)-酮稠杂环化合物及其制备方法 | |
CN102442947B (zh) | 孟鲁司特钠中间体的制备方法 | |
CN104030941A (zh) | 一种3-(4-羟基苯基)丙酰胺的合成方法 | |
CN104447567B (zh) | 一种1位取代苯并咪唑衍生物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201019 Address after: 215600 station 0002, 20th floor, building A-1, shazhouhu science and Technology Innovation Park, Huachang Road, yangshe Town, Zhangjiagang City, Suzhou City, Jiangsu Province (cluster registration) Patentee after: Youbiao e-commerce (Suzhou) Co., Ltd Address before: 215000 Jiangsu Province, Suzhou City Industrial Park Commercial Plaza Building 1 room 1305 Lianfeng Patentee before: SUZHOU MIRACPHARMA TECHNOLOGY Co.,Ltd. Patentee before: Xu Xuenong |